0.50 / AMA PRA Category 1 Credit(s)TM 0.50 / CNE Contact Hour(s)
Jointly provided by Postgraduate Institute for Medicine and Strategic Consultants International
Supported by an educational grant from Takeda Pharmaceuticals, U.S.A. Inc
The traditional ‘step-up’ treatment algorithm for ulcerative colitis (UC) patients, in which the most efficacious drugs are typically used after a patient has failed lower-tier drugs, is still widely utilized. This is despite the American Gastroenterological Association (AGA) recommending choice of UC therapy be determined according to patients’ disease risk. This module summarizes the concept of treating UC patients according to their disease risk using the AGA UC Care Pathway. The rational of risk-stratification is outlined, along with the core components for determining disease risk.
Physicians and registered nurses
Upon completion of this activity, participants should be better able to:
Employ prognostication/risk assessment in addition to symptom severity to develop management plans for patients with UC
Evaluate patients based on risk assessment, disease severity, and prior treatment response and consider the early introduction of biologic therapy when clinically indicated
Describe the protocol for treating low- and high-risk UC patients according to the AGA UC Care Pathway
Accreditor Disclosure of Conflicts of Interest Policy
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported any financial relationships or relationships to products or devices they or their spouse/life partner with commercial interests related to the content of this CME activity under the Faculty section below.
Course Author Thermistocles Dassopoulos, MD Director Baylor Center for Inflammatory Bowel Diseases Baylor University Medical Center at Dallas Dallas, TX
Dr. Dassopoulos discloses the following: Contracted Research: Abbvie, Celegene, Allergan, Eli Lilly
Course Director Miguel D. Regueiro, MD IBD Clinical Medical Director Division of Gastroenterology, Hepatology and Nutrition Department of Medicine University of Pittsburgh School of Medicine Pittsburgh, PA
Dr. Regueiro discloses the following: Consulting Fees: Abbvie, Takeda, Amgen, Janssen, Pfizer, UCB
Joint Provider Disclosures
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, have nothing to disclose. The SCI planners and managers, Ian Morgan MSc, Elena Urso BSc, and Eoin Duffy, PhD, have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 0.50 contact hour(s) is provided by the Postgraduate Institute for Medicine.
Disclosure of Unlabeled Use
This education activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, a review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine AT (303) 799-1930 and via email at firstname.lastname@example.org.